Raymond James Raises ADMA Biologics (NASDAQ:ADMA) Price Target to $25.00

ADMA Biologics (NASDAQ:ADMA - Get Free Report) had its price objective boosted by analysts at Raymond James from $18.00 to $25.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a "strong-buy" rating on the biotechnology company's stock. Raymond James' price target suggests a potential upside of 10.52% from the stock's previous close.

A number of other equities analysts have also commented on ADMA. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of ADMA Biologics in a research note on Monday, October 14th. Cantor Fitzgerald reissued an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $21.25.

ADMA Biologics Stock Performance

Shares of ADMA traded up $2.90 during midday trading on Friday, reaching $22.62. 9,716,919 shares of the stock were exchanged, compared to its average volume of 3,667,173. The stock's 50 day simple moving average is $18.12 and its 200 day simple moving average is $13.84. The company has a market cap of $5.27 billion, a P/E ratio of 161.57 and a beta of 0.64. ADMA Biologics has a twelve month low of $3.60 and a twelve month high of $23.52. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the previous year, the firm posted ($0.02) EPS. The business's revenue for the quarter was up 78.4% compared to the same quarter last year. On average, sell-side analysts expect that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares of the company's stock, valued at approximately $7,589,587.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 over the last three months. Corporate insiders own 3.70% of the company's stock.

Hedge Funds Weigh In On ADMA Biologics

Institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC acquired a new position in ADMA Biologics in the 2nd quarter valued at approximately $29,000. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the third quarter valued at $30,000. EntryPoint Capital LLC bought a new position in ADMA Biologics during the 1st quarter worth $31,000. CWM LLC lifted its holdings in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after buying an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter valued at about $93,000. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.